| Phenotypic Profile |
| Category |
Entity |
Quantity |
Experimental Paradigm |
Age at Testing |
| Circadian sleep/wake cycle |
Locomotor activity in diurnal cycle: dark phase1 |
Increased
Description: cntnap2ab mutants showed significantly greater nighttime activity compared to controls.
|
General observations |
4-6 dpf |
| |
|
Description: cntnap2ab mutants showed significantly greater nighttime activity compared to controls.
|
|
|
| Neuroanatomy / Ultrastructure / Cytoarchitecture |
Brain size1 |
Decreased
Description: cntnap2ab mutants showed a significant decrease in the size of the brain at 96 hpf.
|
Histology |
96 hpf |
| |
|
Description: cntnap2ab mutants showed a significant decrease in the size of the brain at 96 hpf.
|
|
|
| Neuroanatomy / Ultrastructure / Cytoarchitecture |
Neuronal number: interneurons1 |
Decreased
Description: cntnap2ab mutants showed a significant decrease in the number of GABAergic neurons compared to wildtype controls.
Exp Paradigm: Used transgenic line that labels GABAergic neurons and precursors: Tg(dlx6a-1.4kbdlx5a/dlx6a:GFP)
|
Immunohistochemistry |
4 dpf; 28 hpf |
| |
|
Description: cntnap2ab mutants showed a significant decrease in the number of GABAergic neurons compared to wildtype controls.
Exp Paradigm: Used transgenic line that labels GABAergic neurons and precursors: Tg(dlx6a-1.4kbdlx5a/dlx6a:GFP) |
|
|
| Neuroanatomy / Ultrastructure / Cytoarchitecture |
Morphology and size of anterior commissure1 |
Decreased
Description: cntnap2ab mutants showed transient delays in anterior and postoptic commissure formation compared to controls.
|
Immunohistochemistry |
28 hpf |
| |
|
Description: cntnap2ab mutants showed transient delays in anterior and postoptic commissure formation compared to controls.
|
|
|
| Neurophysiology |
Apoptosis: brain cells1 |
Decreased
Description: cntnap2ab mutants showed a significant decrease in the brain size compared to controls.
|
Immunohistochemistry |
96 hpf |
| |
|
Description: cntnap2ab mutants showed a significant decrease in the brain size compared to controls.
|
|
|
| Seizure |
Seizure threshold1 |
Decreased
Description: cntnap2ab mutants showed increased sensitivity to pentylenetetrazol-induced seizures (10 mM dose) compared to controls.
Exp Paradigm: Pentylenetetrazol
|
Observation of chemically induced seizures |
6 dpf |
| |
|
Description: cntnap2ab mutants showed increased sensitivity to pentylenetetrazol-induced seizures (10 mM dose) compared to controls.
Exp Paradigm: Pentylenetetrazol |
|
|
| Seizure |
Seizures1 |
Increased
Description: cntnap2ab mutants showed increased activity levels following the treatment with pentylenetetrazol compared to controls.
Exp Paradigm: Pentylenetetrazol
|
Observation of chemically induced seizures |
6 dpf |
| |
|
Description: cntnap2ab mutants showed increased activity levels following the treatment with pentylenetetrazol compared to controls.
Exp Paradigm: Pentylenetetrazol |
|
|
| Seizure |
Seizure threshold1 |
Decreased
Description: cntnap2ab mutants showed increased sensitivity to pentylenetetrazol-induced seizures (5-15 mM doses) compared to controls.
Exp Paradigm: Pentylenetetrazol
|
Observation of chemically induced seizures |
4 dpf |
| |
|
Description: cntnap2ab mutants showed increased sensitivity to pentylenetetrazol-induced seizures (5-15 mM doses) compared to controls.
Exp Paradigm: Pentylenetetrazol |
|
|
| Sensory |
Startle response: acoustic stimulus1 |
Decreased
Description: cntnap2ab mutants showed a decrease in acoustic (13, 19.8 dB) startle response compared to controls.
Exp Paradigm: Long latency C-bend (SLC) sensitivity
|
Startle response test |
5-7 dpf |
| |
|
Description: cntnap2ab mutants showed a decrease in acoustic (13, 19.8 dB) startle response compared to controls.
Exp Paradigm: Long latency C-bend (SLC) sensitivity |
|
|
| Sensory |
Visual motor response1 |
Abnormal
Description: cntnap2ab mutants showed No Change in optokinetic response performance at most contrast sensitivities (5-70%), though at the highest contrast level (100%), cntnap2ab mutants displayed significantly lower optokinetic response performance compared to controls.
|
Eye movement recording |
5-7 dpf |
| |
|
Description: cntnap2ab mutants showed No Change in optokinetic response performance at most contrast sensitivities (5-70%), though at the highest contrast level (100%), cntnap2ab mutants displayed significantly lower optokinetic response performance compared to controls.
|
|
|
| Developmental profile |
Size/growth1 |
Decreased
Description: cntnap2ab mutants showed a significant decrease in the head size compared to controls.
|
Immunohistochemistry |
30; 96 hpf |
| |
|
Description: cntnap2ab mutants showed a significant decrease in the head size compared to controls.
|
|
|
| Developmental profile |
Eye development: eye size1 |
Decreased
Description: cntnap2ab mutants showed a significant decrease in the eye size compared to controls.
|
Immunohistochemistry |
30 hpf; 96 hpf |
| |
|
Description: cntnap2ab mutants showed a significant decrease in the eye size compared to controls.
|
|
|
| Emotion |
Habituation to aversive stimuli1 |
No change |
Startle response test |
5-7 dpf |
| Molecular profile |
Cell proliferation1 |
No change |
Phospho-histone 3 expression |
48 hpf |
| Motor phenotype |
Spontaneous and reflexive eye movements1 |
No change |
Eye movement recording |
5-7 dpf |
| Neuroanatomy / Ultrastructure / Cytoarchitecture |
Anatomical projections and connectivity1 |
No change |
Immunohistochemistry |
48 hpf; 5hpf |
| Neuroanatomy / Ultrastructure / Cytoarchitecture |
Neuronal number: excitatory neurons1 |
No change |
Immunohistochemistry |
4 dpf |
| Neurophysiology |
Apoptosis: brain cells1 |
No change |
Tunel assay |
28 hpf |
| Sensory |
Sensorimotor gating1 |
No change |
Prepulse inhibition |
5-7 dpf |
| Sensory |
Startle response: acoustic stimulus1 |
No change |
Startle response test |
5-7 dpf |
|
| Not Reported: |
Circadian sleep/wake cycle, Communications, Immune response, Learning & memory, Maternal behavior, Physiological parameters, Repetitive behavior, Social behavior, |
